Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  D’Souza, Warren N ^a   Douangpanya, Jason ^b   Mu, Sharon ^a   Jaeckel, Peter ^c   Zhang, Ming ^a   Maxwell, Joseph R ^b   Rottman, James B ^a   Labitzke, Katja ^c   Willee, Angela ^a   Beckmann, Holger ^c   Wang, Yingcai ^a   Li, Yang ^a   Schwandner, Ralf ^c   Johnston, James A ^a   Towne, Jennifer E ^b   Hsu, Hailing ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c Amgen Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GPR43 PROTEIN; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; CYTOKINE; G-PROTEIN COUPLED RECEPTOR 43, HUMAN; VOLATILE FATTY ACID;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INTESTINAL BARRIER; INTESTINE EPITHELIUM CELL; LYMPHOCYTE PROLIFERATION; PERMEABILITY BARRIER; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; T LYMPHOCYTE; AGONISTS; ANIMAL; CACO-2 CELL LINE; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; EPITHELIUM CELL; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MONONUCLEAR CELL; MOUSE;

ANIMALS; CACO-2 CELLS; CELL LINE; CELL PROLIFERATION; CYTOKINES; EPITHELIAL CELLS; FATTY ACIDS, VOLATILE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MICE; RECEPTORS, CELL SURFACE;

EID: 85024846678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0180190     Document Type: Article

References (50)

1. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clinical and experimental immunology. 1995; 102(3):448–55. Epub 1995/12/01. PMID: 8536356; PubMed Central PMCID: PMCPmc1553362.
2. Boismenu R, Chen Y. Insights from mouse models of colitis. Journal of leukocyte biology. 2000; 67 (3):267–78. Epub 2000/03/25. PMID: 10733087.
3. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(34):13780–5. Epub 2007/08/19. https://doi.org/10.1073/pnas.0706625104 PMID: 17699621; PubMed Central PMCID: PMCPmc1959459.
4. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene cata-logue established by metagenomic sequencing. Nature. 2010; 464(7285):59–65. Epub 2010/03/06. https://doi.org/10.1038/nature08821 PMID: 20203603; PubMed Central PMCID: PMCPmc3779803.
5. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122(1):44–54. https://doi.org/10.1053/gast.2002.30294 PMID: 11781279
6. Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999; 117(5):1089–97. Epub 1999/10/27. PMID: 10535871.
7. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006; 55(2):205–11. Epub 2005/09/29. https://doi.org/10.1136/gut.2005.073817 PMID: 16188921; PubMed Central PMCID: PMCPmc1856500.
8. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory bowel diseases. 2011; 17(1):362–81. Epub 2010/08/21. https://doi.org/10.1002/ibd.21403 PMID: 20725949.
9. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119–24. Epub 2012/11/07. https://doi.org/10.1038/nature11582 PMID: 23128233; PubMed Central PMCID: PMCPmc3491803.
10. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474(7351):307–17. https://doi.org/10.1038/nature10209 PMID: 21677747; PubMed Central PMCID: PMC3204665.
11. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut. 1994; 35(1 Suppl):S35–8. Epub 1994/01/01. PMID: 8125387; PubMed Central PMCID: PMCPmc1378144.
12. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987; 28(10):1221–7. Epub 1987/10/01. PMID: 3678950; PubMed Central PMCID: PMCPmc1433442.
13. Mariadason JM, Barkla DH, Gibson PR. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. The American journal of physiology. 1997; 272(4 Pt 1):G705–12. Epub 1997/04/01. PMID: 9142899.
14. Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scandinavian journal of gastroenterology. 2000; 35(10):1053–9. Epub 2000/12/01. PMID: 11099058.
15. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatric research. 2007; 61(1):37–41. Epub 2007/01/11. https://doi.org/10.1203/01.pdr.0000250014.92242.f3 PMID: 17211138.
16. Suzuki T, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. The British journal of nutrition. 2008; 100(2):297–305. https://doi.org/10.1017/S0007114508888733 PMID: 18346306.
17. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Digestive diseases and sciences. 2012; 57(12):3126–35. Epub 2012/06/12. https://doi.org/10.1007/s10620-012-2259-4 PMID: 22684624.
18. Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology. 1997; 113(2):487–96. Epub 1997/08/01. PMID: 9247468.
19. Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2000; 14(15):2380–2. Epub 2000/10/12. https://doi.org/10.1096/fj.00-0359fje PMID: 11024006.
20. Nancey S, Bienvenu J, Coffin B, Andre F, Descos L, Flourie B. Butyrate strongly inhibits in vitro stimulated release of cytokines in blood. Digestive diseases and sciences. 2002; 47(4):921–8. Epub 2002/ 05/07. PMID: 11991629.
21. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(6):2247–52. Epub 2014/01/07. https://doi.org/10.1073/pnas.1322269111 PMID: 24390544; PubMed Central PMCID: PMCPmc3926023.
22. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World journal of gastroenterology: WJG. 2007; 13(20):2826–32. Epub 2007/06/15. https://doi.org/10.3748/wjg.v13.i20.2826 PMID: 17569118.
23. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504(7480):446–50. Epub 2013/11/15. https://doi.org/10.1038/nature12721 PMID: 24226770.
24. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504(7480):451–5. https://doi.org/10.1038/nature12726 PMID: 24226773; PubMed Central PMCID: PMC3869884.
25. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013; 341(6145):569–73. https://doi.org/10.1126/science.1241165 PMID: 23828891; PubMed Central PMCID: PMC3807819.
26. Eftimiadi C, Buzzi E, Tonetti M, Buffa P, Buffa D, van Steenbergen MT, et al. Short-chain fatty acids produced by anaerobic bacteria alter the physiological responses of human neutrophils to chemotactic peptide. The Journal of infection. 1987; 14(1):43–53. Epub 1987/01/01. PMID: 3819457.
27. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011; 3(10):858–76. https://doi.org/10.3390/nu3100858 PMID: 22254083; PubMed Central PMCID: PMC3257741.
28. Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut. 1996; 38(4):568–73. Epub 1996/04/01. PMID: 8707089; PubMed Central PMCID: PMCPmc1383116.
29. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut. 2000; 47(3):397–403. Epub 2000/08/15. PubMed Central PMCID: PMCPmc1728045. https://doi.org/10.1136/gut.47.3.397 PMID: 10940278
30. Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. Journal of gastroenterology. 2000; 35(5):341–6. Epub 2000/06/01. PMID: 10832668.
31. Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A, Patra S. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. American journal of physiology Gastrointestinal and liver physiology. 2003; 285(1):G177–84. Epub 2003/03/15. https://doi.org/10.1152/ajpgi.00307.2002 PMID: 12637250.
32. Vieira EL, Leonel AJ, Sad AP, Beltrao NR, Costa TF, Ferreira TM, et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. The Journal of nutritional biochemistry. 2012; 23(5):430–6. https://doi.org/10.1016/j.jnutbio.2011.01.007 PMID: 21658926.
33. Mishiro T, Kusunoki R, Otani A, Ansary MM, Tongu M, Harashima N, et al. Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8. Laboratory investigation; a journal of technical methods and pathology. 2013; 93(7):834–43. Epub 2013/06/12. https://doi.org/10.1038/labinvest.2013.70 PMID: 23752130.
34. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009; 461(7268):1282–6. https://doi.org/10.1038/nature08530 PMID: 19865172; PubMed Central PMCID: PMC3256734.
35. Masui R, Sasaki M, Funaki Y, Ogasawara N, Mizuno M, Iida A, et al. G protein-coupled receptor 43 moderates gut inflammation through cytokine regulation from mononuclear cells. Inflammatory bowel diseases. 2013; 19(13):2848–56. https://doi.org/10.1097/01.MIB.0000435444.14860.ea PMID: 24141712.
36. Soldavini J, Kaunitz JD. Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Digestive diseases and sciences. 2013; 58(10):2756–66. https://doi.org/10.1007/s10620-013-2744-4 PMID: 23839339.
37. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. The Journal of biological chemistry. 2003; 278(28):25481–9. https://doi.org/10.1074/jbc.M301403200 PMID: 12711604.
38. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. The Journal of biological chemistry. 2003; 278(13):11312–9. https://doi.org/10.1074/jbc.M211609200 PMID: 12496283.
39. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochemical and Biophysical Research Communications. 2003; 303(4):1047–52. https://doi.org/10.1016/s0006-291x(03)00488-1 PMID: 12684041
40. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer research. 2009; 69(7):2826–32. Epub 2009/03/12. https://doi.org/10.1158/0008-5472.CAN-08-4466 PMID: 19276343; PubMed Central PMCID: PMCPmc3747834.
41. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, et al. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Molecular pharmacology. 2008; 74(6):1599–609. Epub 2008/09/27. https://doi.org/10.1124/mol.108.049536 PMID: 18818303.
42. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, et al. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Bioorganic & medicinal chemistry letters. 2010; 20(2):493–8. Epub 2009/12/17. https://doi.org/10.1016/j.bmcl.2009.11.112 PMID: 20005104.
43. Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase pros-taglandin E2 secretion in human peripheral blood mononuclear cells. Nutrition research. 2008; 28 (5):321–8. https://doi.org/10.1016/j.nutres.2008.02.012 PMID: 19083427.
44. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013; 145(2):396–406 e1-10. https://doi.org/10.1053/j.gastro.2013.04.056 PMID: 23665276.
45. Sina C, Gavrilova O, Forster M, Till A, Derer S, Hildebrand F, et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. Journal of immunology. 2009; 183 (11):7514–22. Epub 2009/11/18. https://doi.org/10.4049/jimmunol.0900063 PMID: 19917676.
46. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly YM, et al. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PloS one. 2011; 6(6):e21205. https://doi.org/10.1371/journal.pone.0021205 PMID: 21698257; PubMed Central PMCID: PMC3115979.
47. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nature medicine. 2014; 20(2):159–66. https://doi.org/10.1038/nm.3444 PMID: 24390308.
48. Aoyama M, Kotani J, Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition. 2010; 26(6):653–61. https://doi.org/10.1016/j.nut.2009.07.006 PMID: 20004081.
49. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal immunology. 2015; 8(1):80–93. Epub 2014/06/12. https://doi.org/10.1038/mi.2014.44 PMID: 24917457; PubMed Central PMCID: PMCPmc4263689.
50. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014; 40(1):128–39. https://doi.org/10.1016/j.immuni.2013.12.007 PMID: 24412617.